F10 and intracerebral hemorrhage: Compared to warfarin, fXa inhibitors appear to have a lower rate of intracerebral hemorrhage, with annual rates of 0.1–0.2% compared to 0.3–0.6% of patients on warfarin.3,4 However, whereas four-factor prothrombin complex concentrate (4F-PCC) and vitamin K are generally considered the standard of care for reversal of life-threatening bleeding secondary to warfarin (due to warfarin’s availability it has been more extensively studied), reversal of fXa inhibitors in this setting remains controversial due to a lack of high-quality evidence.5–8